These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 14670831)

  • 1. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond.
    Yan SF; Ramasamy R; Naka Y; Schmidt AM
    Circ Res; 2003 Dec; 93(12):1159-69. PubMed ID: 14670831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The RAGE axis and endothelial dysfunction: maladaptive roles in the diabetic vasculature and beyond.
    Ramasamy R; Yan SF; Schmidt AM
    Trends Cardiovasc Med; 2005 Oct; 15(7):237-43. PubMed ID: 16226677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging.
    Yan SF; D'Agati V; Schmidt AM; Ramasamy R
    Curr Mol Med; 2007 Dec; 7(8):699-710. PubMed ID: 18331228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications.
    Yan SF; Ramasamy R; Schmidt AM
    Nat Clin Pract Endocrinol Metab; 2008 May; 4(5):285-93. PubMed ID: 18332897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAGE: a journey from the complications of diabetes to disorders of the nervous system - striking a fine balance between injury and repair.
    Rong LL; Gooch C; Szabolcs M; Herold KC; Lalla E; Hays AP; Yan SF; Yan SS; Schmidt AM
    Restor Neurol Neurosci; 2005; 23(5-6):355-65. PubMed ID: 16477098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor for advanced glycation end products and the cardiovascular complications of diabetes and beyond: lessons from AGEing.
    Yan SF; Yan SD; Herold K; Ramsamy R; Schmidt AM
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):511-24, viii. PubMed ID: 16959583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis.
    Kim W; Hudson BI; Moser B; Guo J; Rong LL; Lu Y; Qu W; Lalla E; Lerner S; Chen Y; Yan SS; D'Agati V; Naka Y; Ramasamy R; Herold K; Yan SF; Schmidt AM
    Ann N Y Acad Sci; 2005 Jun; 1043():553-61. PubMed ID: 16037278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The AGE/RAGE axis in diabetes-accelerated atherosclerosis.
    Jandeleit-Dahm K; Watson A; Soro-Paavonen A
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):329-34. PubMed ID: 18290873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts.
    Park L; Raman KG; Lee KJ; Lu Y; Ferran LJ; Chow WS; Stern D; Schmidt AM
    Nat Med; 1998 Sep; 4(9):1025-31. PubMed ID: 9734395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation.
    Schmidt AM; Hofmann M; Taguchi A; Yan SD; Stern DM
    Semin Thromb Hemost; 2000; 26(5):485-93. PubMed ID: 11129404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAGE axis: Animal models and novel insights into the vascular complications of diabetes.
    Naka Y; Bucciarelli LG; Wendt T; Lee LK; Rong LL; Ramasamy R; Yan SF; Schmidt AM
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1342-9. PubMed ID: 15155381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldose reductase and AGE-RAGE pathways: key players in myocardial ischemic injury.
    Kaneko M; Bucciarelli L; Hwang YC; Lee L; Yan SF; Schmidt AM; Ramasamy R
    Ann N Y Acad Sci; 2005 Jun; 1043():702-9. PubMed ID: 16037296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAGE, vascular tone and vascular disease.
    Farmer DG; Kennedy S
    Pharmacol Ther; 2009 Nov; 124(2):185-94. PubMed ID: 19616578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress.
    Herold K; Moser B; Chen Y; Zeng S; Yan SF; Ramasamy R; Emond J; Clynes R; Schmidt AM
    J Leukoc Biol; 2007 Aug; 82(2):204-12. PubMed ID: 17513693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Red blood cell adhesion in diabetes mellitus is mediated by advanced glycation end product receptor and is modulated by nitric oxide.
    Grossin N; Wautier MP; Wautier JL
    Biorheology; 2009; 46(1):63-72. PubMed ID: 19252229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes.
    Wendt T; Bucciarelli L; Qu W; Lu Y; Yan SF; Stern DM; Schmidt AM
    Curr Atheroscler Rep; 2002 May; 4(3):228-37. PubMed ID: 11931721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes.
    Rojas A; Morales MA
    Life Sci; 2004 Dec; 76(7):715-30. PubMed ID: 15581904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AGE, RAGE, and ROS in diabetic nephropathy.
    Tan AL; Forbes JM; Cooper ME
    Semin Nephrol; 2007 Mar; 27(2):130-43. PubMed ID: 17418682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts.
    Ramasamy R; Yan SF; Schmidt AM
    J Leukoc Biol; 2009 Sep; 86(3):505-12. PubMed ID: 19477910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAGE in inflammation: a new therapeutic target?
    Bierhaus A; Stern DM; Nawroth PP
    Curr Opin Investig Drugs; 2006 Nov; 7(11):985-91. PubMed ID: 17117586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.